Evidence map›Paper›PMID 37559126›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Fibronectin fragments generated by pancreatic trypsin act as endogenous inhibitors of pancreatic tumor growth.

Andrea Resovi, Perla Persichitti, Laura Brunelli, Lucia Minoli, Patrizia Borsotti, Giulia Garattini, Matteo Tironi, Erica Dugnani, Miriam Redegalli, Giulia De Simone and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Andrea ResoviDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Perla PersichittiDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Laura BrunelliDepartment of Environmental Science, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Lucia MinoliDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Patrizia BorsottiDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Giulia GarattiniDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Matteo TironiDepartment of Biomedical Engineering, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Erica DugnaniDiabetes Research Institute, IRCCS Ospedale San Raffaele, Milano, Italy.
Miriam RedegalliDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Giulia De SimoneDepartment of Environmental Science, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Roberta PastorelliDepartment of Environmental Science, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Maria Rosa BaniDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Lorenzo PiemontiDiabetes Research Institute, IRCCS Ospedale San Raffaele, Milano, Italy.
Deane F MosherDepartments of Biomolecular Chemistry and Medicine, University of Wisconsin, Madison, WI, USA.
Raffaella GiavazziDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Giulia TarabolettiDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy.
Dorina BelottiDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo and Milan, Italy. dorina.belotti@marionegri.it.ORCID http://orcid.org/0000-0002-3868-9144
Mario Negri Institute for Pharmacological Research · ITIRCCS Ospedale San Raffaele · ITUniversity of Wisconsin–Madison · US

Funding

Associazione Italiana per la Ricerca sul Cancro IG 2019 ID 23443Fondazione Cariplo 2019-1609
6 · The paper itself

Abstract

backgroundThe pancreatic microenvironment has a defensive role against cancer but it can acquire tumor-promoting properties triggered by multiple mechanisms including alterations in the equilibrium between proteases and their inhibitors. The identification of proteolytic events, targets and pathways would set the basis for the design of new therapeutic approaches. METHODS AND

resultsHere we demonstrate that spheroids isolated from human and murine healthy pancreas and co-transplanted orthotopically with pancreatic ductal adenocarcinoma (PDAC) in mouse pancreas inhibited tumor growth. The effect was mediated by trypsin-generated fibronectin (FN) fragments released by pancreatic spheroids. Tumor inhibition was observed also in a model of acute pancreatitis associated with trypsin activation. Mass spectrometry proteomic analysis of fragments and mAb against different FN epitopes identified the FN type III domain as responsible for the activity. By inhibiting integrin α5β1, FAK and FGFR1 signaling, the fragments induced tumor cell detachment and reduced cell proliferation. Consistent with the mutual relationship between the two pathways, FGF2 restored both FGFR1 and FAK signaling and promoted PDAC cell adhesion and proliferation. FAK and FGFR inhibitors additively inhibited PDAC growth in vitro and in orthotopic in vivo models.

conclusionsThis study identifies a novel role for pancreatic trypsin and fibronectin cleavage as a mechanism of protection against cancer by the pancreatic microenvironment. The finding of a FAK-FGFR cross-talk in PDAC support the combination of FAK and FGFR inhibitors for PDAC treatment to emulate the protective effect of the normal pancreas against cancer.

Indexed as

Carcinoma, Pancreatic DuctalFibronectinsPancreatic NeoplasmsPancreatitisAcute DiseaseAnimalsCell Line, TumorCell ProliferationHumansMicePancreasProteomicsTrypsinTumor MicroenvironmentFibronectinsTrypsinFAKFGFRFibronectinPDACTrypsin

Identifiers

PMID37559126
PMCPMC10411016
OpenAlexW4385705407

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.